Rallybio, a New Haven biotech, has acquired from Sanofi worldwide exclusive rights to develop a drug candidate designed to treat patients with severe anemia from certain blood disorders.
Sanofi’s KY1066 will be renamed RLYB331. RLYB331 will fit into Rallybio’s pipeline, which has a focus on hematology and rare diseases. The biotech’s lead asset is in a phase 1/2 study for a rare fetal bleeding disorder.